GlassScriptPhysician profile
Brytney Snow Cobia
NPI 1265811970
$3,144.98
in general payments reported to CMS, 2019-2025
21 companies · $36.32 in 2025
The $36.32 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $389 · 2021: $768 · 2022: $571 · 2023: $650 · 2024: $617 · 2025: $36.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $852.95 | 2019-2024 | Xarelto |
| Pfizer INC. | $700.10 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $219.20 | 2019-2024 | |
| Novo Nordisk INC | $175.33 | 2023-2025 | Wegovy |
| Gilead Sciences, INC. | $174.61 | 2021-2024 | Veklury |
| Alexion Pharmaceuticals, INC. | $170.10 | 2021-2023 | Soliris, Ultomiris |
| Lilly USA, LLC | $128.56 | 2024 | Zepbound |
| Abbvie INC. | $121.89 | 2021-2025 | Dalvance |
| Astrazeneca Pharmaceuticals LP | $75.34 | 2020-2023 | Lokelma |
| Silk Road Medical, INC. | $72.32 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Inari Medical, INC. | $65.92 | 2021-2022 | |
| Melinta Therapeutics, LLC | $63.05 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.38 | 2021-2024 | Lifevest |
| Galderma Laboratories, L.P. | $52.18 | 2023 | Dysport |
| E.R. Squibb & Sons, L.L.C. | $47.91 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $39.59 | 2021 | |
| Merck Sharp & Dohme LLC | $36.43 | 2020-2021 | |
| Impulse Dynamics (USA) INC. | $28.92 | 2022 | |
| Abbott Laboratories | $23.67 | 2021 | |
| Allergan, INC. | $20.46 | 2020 | |
| Chiesi USA, INC. | $17.07 | 2023 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brytney Cobia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.